• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    US Hospital Acquired infections Market

    ID: MRFR/MED/11471-HCR
    100 Pages
    Garvit Vyas
    October 2025

    US Hospital-Acquired Infections Market US Hospital-Acquired Infections Market Research Report: By Pathogen Type (Bacteria, Viruses, Fungi, Parasites), By Infection Type (Surgical Site Infections, Ventilator-Associated Pneumonia, Catheter-Associated Urinary Tract Infections, Bloodstream Infections), By Hospital Department (Intensive Care Unit, Surgery Department, Emergency Department, Pediatric Department) and By Treatment Type (Infection Control Products, Antibiotics, Disinfectants, Vaccines) - Forecast to ...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Hospital Acquired infections Market Infographic
    Purchase Options

    US Hospital Acquired infections Market Summary

    As per MRFR analysis, the US size was estimated at 8.5 USD Billion in 2024.. The US hospital acquired-infections market is projected to grow from 8.66 USD Billion in 2025 to 10.5 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 1.94% during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The US The hospital-acquired infections market is experiencing a robust shift towards enhanced infection prevention and control measures..

    • The market is witnessing a rising focus on infection prevention, driven by increased regulatory scrutiny and heightened awareness of patient safety.
    • Technological advancements in monitoring are becoming pivotal in managing hospital acquired-infections, particularly in the largest segment of surgical site infections.
    • Antimicrobial stewardship initiatives are gaining traction, reflecting a growing commitment to responsible antibiotic use in healthcare settings.
    • Key market drivers include advancements in infection control technologies and rising healthcare expenditure, which are propelling growth in the fastest-growing segment of urinary tract infections.

    Market Size & Forecast

    2024 Market Size 8.5 (USD Billion)
    2035 Market Size 10.5 (USD Billion)

    Major Players

    Johnson & Johnson (US), Becton Dickinson and Company (US), 3M Company (US), Medtronic plc (IE), Stryker Corporation (US), Abbott Laboratories (US), Cardinal Health, Inc. (US), Thermo Fisher Scientific Inc. (US)

    US Hospital Acquired infections Market Trends

    The hospital-acquired infections market is experiencing notable shifts driven by various factors.. Increased awareness regarding infection control and prevention measures has led to heightened demand for effective solutions. Healthcare facilities are prioritizing the implementation of stringent protocols to mitigate the risk of infections acquired during hospital stays. This trend is further supported by regulatory bodies advocating for improved patient safety standards, which in turn influences purchasing decisions within the market. As a result, manufacturers are focusing on developing innovative products that align with these evolving requirements. Moreover, advancements in technology are playing a crucial role in shaping the landscape of the hospital acquired-infections market. The integration of digital health solutions, such as real-time monitoring systems and data analytics, appears to enhance infection control efforts. These technologies facilitate timely interventions and improve overall patient outcomes. Additionally, the growing emphasis on antimicrobial stewardship programs indicates a shift towards more responsible use of antibiotics, which may help reduce the incidence of resistant infections. Overall, the hospital acquired-infections market is poised for growth as stakeholders adapt to emerging challenges and opportunities.

    Rising Focus on Infection Prevention

    There is an increasing emphasis on infection prevention strategies within healthcare settings. Hospitals are adopting comprehensive protocols to minimize the risk of hospital acquired infections. This trend is driven by regulatory requirements and a commitment to patient safety.

    Technological Advancements in Monitoring

    Innovations in technology are transforming infection control practices. The use of real-time monitoring systems and data analytics is becoming more prevalent, enabling healthcare providers to respond swiftly to potential outbreaks and improve patient care.

    Antimicrobial Stewardship Initiatives

    The hospital-acquired infections market is seeing a growing focus on antimicrobial stewardship.. Programs aimed at optimizing antibiotic use are being implemented to combat the rise of resistant infections, thereby enhancing patient outcomes and safety.

    US Hospital Acquired infections Market Drivers

    Growing Patient Population

    The hospital acquired-infections market is significantly influenced by the growing patient population in the United States. As the population ages and the prevalence of chronic diseases increases, more individuals are seeking medical care, leading to higher hospital admissions. According to the U.S. Census Bureau, the population aged 65 and older is projected to reach 80 million by 2040, which will likely result in an increased number of surgical procedures and hospital stays. This demographic shift creates a larger pool of patients who are at risk for hospital acquired infections. Consequently, healthcare facilities are compelled to enhance their infection control measures to protect vulnerable populations. The rising patient volume is expected to drive demand for innovative solutions in the hospital acquired-infections market, as hospitals strive to minimize infection rates and improve patient outcomes.

    Increased Regulatory Scrutiny

    The hospital acquired-infections market is experiencing heightened regulatory scrutiny as healthcare authorities implement stricter guidelines to combat infection rates. Regulatory bodies, such as the Centers for Disease Control and Prevention (CDC) and the Centers for Medicare & Medicaid Services (CMS), are enforcing compliance measures that require hospitals to adopt rigorous infection control protocols. This regulatory environment is likely to drive investments in advanced infection prevention technologies and practices. Hospitals that fail to comply may face financial penalties, which could reach millions of dollars annually. As a result, the market is witnessing a surge in demand for products and services that ensure compliance with these regulations, thereby fostering growth in the hospital acquired-infections market. The emphasis on accountability and transparency in infection reporting is also expected to enhance the overall quality of care provided to patients.

    Rising Healthcare Expenditure

    The hospital-acquired infections market is poised for growth due to rising healthcare expenditure in the United States.. Increased funding for healthcare services allows hospitals to invest in advanced infection prevention measures and technologies. According to the National Health Expenditure Accounts, healthcare spending in the U.S. is projected to reach $6 trillion by 2027, which will likely include significant allocations for infection control initiatives. This financial commitment enables healthcare facilities to implement comprehensive infection prevention programs, hire specialized staff, and procure state-of-the-art equipment. As hospitals strive to enhance patient safety and reduce infection rates, the hospital acquired-infections market is expected to benefit from this upward trend in healthcare spending, leading to improved outcomes for patients and healthcare providers alike.

    Heightened Awareness of Patient Safety

    The hospital-acquired infections market is increasingly driven by heightened awareness of patient safety among healthcare providers and patients alike.. As information regarding the risks associated with hospital acquired infections becomes more widely disseminated, there is a growing demand for effective infection prevention strategies. Healthcare organizations are prioritizing patient safety initiatives, which often include comprehensive training programs for staff and the implementation of best practices in infection control. This cultural shift towards prioritizing patient safety is likely to result in increased investments in the hospital acquired-infections market, as hospitals seek to adopt evidence-based practices and technologies that minimize infection risks. Furthermore, patient advocacy groups are actively promoting awareness campaigns, further influencing healthcare providers to enhance their infection prevention efforts.

    Advancements in Infection Control Technologies

    The hospital-acquired infections market is benefiting from advancements in infection control technologies that enhance the ability to prevent and manage infections.. Innovations such as automated disinfection systems, real-time monitoring devices, and advanced sterilization techniques are becoming increasingly prevalent in healthcare settings. For instance, the market for automated disinfection systems is projected to grow at a CAGR of 15% from 2025 to 2030, reflecting the increasing reliance on technology to mitigate infection risks. These technologies not only improve the efficiency of infection control practices but also provide healthcare professionals with valuable data to make informed decisions. As hospitals adopt these cutting-edge solutions, the hospital acquired-infections market is likely to expand, driven by the need for effective infection prevention strategies in an evolving healthcare landscape.

    Market Segment Insights

    By Pathogen Type: Bacteria (Largest) vs. Viruses (Fastest-Growing)

    The market share distribution among the pathogen types reveals that bacteria account for the largest share in the US hospital acquired-infections market. This dominance is primarily due to the prevalence of bacterial infections in healthcare settings, driven by factors such as antibiotic resistance and the high incidence of surgical site infections. In contrast, viruses, while holding a smaller share, are witnessing rapid growth as new viral infections emerge and affect hospital populations, particularly with the rise of healthcare-associated viral outbreaks. Growth trends indicate that the pathogen type segment is evolving, with a significant shift towards addressing viral infections, making them the fastest-growing area. This growth is propelled by advancements in molecular diagnostic techniques and a focus on infection prevention strategies. Bacteria remain a key focus due to their impact on patient morbidity, but the changing landscape of infectious diseases necessitates an adaptive approach, with increasing investments in research and monitoring of all pathogen types.

    Bacteria (Dominant) vs. Viruses (Emerging)

    Bacteria, as the dominant pathogen type in the US hospital acquired-infections market, are primarily characterized by their ability to develop resistance to antibiotics, complicating treatment options and increasing patient risk. This segment includes notable pathogens such as Staphylococcus aureus and Clostridium difficile, which lead to significant morbidity and extended hospital stays. In contrast, viruses represent an emerging segment that is gaining attention due to their increasing role in infections, particularly in immunocompromised patients. Viral outbreaks, driven by pathogens like influenza and norovirus, are prompting hospitals to enhance their infection control measures. Both segments require tailored strategies for effective management, emphasizing the importance of surveillance, prevention, and novel therapeutic approaches to mitigate risks.

    By Infection Type: Surgical Site Infections (Largest) vs. Catheter-Associated Urinary Tract Infections (Fastest-Growing)

    Surgical Site Infections (SSIs) hold the largest market share within the US hospital acquired-infections market, reflecting their significant contribution to overall healthcare challenges. In contrast, Catheter-Associated Urinary Tract Infections (CAUTIs) are rapidly gaining prominence, marking them as an emerging segment. This distribution underscores the varying priorities and challenges faced by healthcare providers in addressing these infections. The growth trends indicate that while SSIs continue to affect a substantial number of patients post-surgery, the increasing awareness and implementation of preventive measures are enhancing the focus on CAUTIs. Factors such as advancements in catheter technology and increased monitoring in hospitals contribute to the burgeoning growth of CAUTIs, representing a shift towards improved patient care and infection control strategies.

    Surgical Site Infections (Dominant) vs. Catheter-Associated Urinary Tract Infections (Emerging)

    Surgical Site Infections are considered the dominant player in the US hospital acquired-infections market due to their direct impact on surgical outcomes and healthcare costs. They often lead to extended hospital stays, additional surgeries, and increased morbidity, compelling healthcare systems to invest in effective prevention strategies. On the other hand, Catheter-Associated Urinary Tract Infections are emerging as a significant concern, driven by the rise in catheter use and heightened attention to urinary tract infection prevention. Enhanced regulations and innovative catheter designs are addressing the challenges posed by CAUTIs, signaling a growing recognition of the need for proactive measures in infection management.

    By Hospital Department: Intensive Care Unit (Largest) vs. Surgery Department (Fastest-Growing)

    The market share distribution among the hospital departments indicates that the Intensive Care Unit holds the largest share within the US hospital acquired-infections market. Its critical role in patient care, especially for those with severe infections, contributes significantly to its dominant position. In contrast, the Surgery Department is emerging as a fast-growing segment due to increasing surgical procedures and heightened awareness about infection control practices in surgical settings. Growth trends show a clear upward trajectory for both segments. The Intensive Care Unit is benefiting from advancements in infection prevention technologies and strict adherence to hygiene protocols. Meanwhile, the Surgery Department's growth is propelled by the rise in elective surgeries and the adoption of minimally invasive techniques, which demand rigorous infection control measures to mitigate hospital-acquired infections.

    Intensive Care Unit (Dominant) vs. Surgery Department (Emerging)

    The Intensive Care Unit represents the dominant segment within the hospital departments, characterized by its essential function in managing critically ill patients, who often present with complex infection challenges. With a focus on intensive monitoring and rapid response to infections, this segment enjoys robust resources and expertise dedicated to infection prevention. On the other hand, the Surgery Department is categorized as emerging, driven by the increased frequency of surgical interventions across various specialties. This department is witnessing an evolution in infection control practices, incorporating advanced sterilization techniques and protocols to enhance patient safety during surgical procedures.

    By Treatment Type: Antibiotics (Largest) vs. Vaccines (Fastest-Growing)

    In the US hospital acquired-infections market, the primary treatment types include Infection Control Products, Antibiotics, Disinfectants, and Vaccines. Among these, Antibiotics hold the largest market share due to their critical role in combating bacterial infections prevalent in hospital settings. Infection Control Products and Disinfectants also contribute significantly, but their market shares are comparatively lower than that of Antibiotics. Meanwhile, Vaccines are emerging as a notable segment, evolving with new developments and higher acceptance in hospitals. Growth trends in this segment indicate a rising demand for innovative Antibiotics and effective Vaccines. The increasing incidence of hospital-acquired infections drives the need for these treatments. Furthermore, advancements in medical technology and increasing awareness about infection control are propelling the development and adoption of Disinfectants and Infection Control Products, solidifying their relevance in enhancing hospital safety protocols.

    Antibiotics (Dominant) vs. Vaccines (Emerging)

    Antibiotics play a dominant role in the treatment of hospital-acquired infections, being a crucial part of the therapeutic arsenal used to combat multidrug-resistant organisms in healthcare settings. They are often the first line of defense in treating infections and have a broad spectrum of applications. As resistance patterns evolve, ongoing innovation and development in antibiotic formulations are vital for sustained effectiveness. On the other hand, Vaccines represent an emerging segment in this market, gaining traction due to their potential to prevent infections proactively. Their development is supported by increasing health policies aimed at preventive care, thus ensuring hospitals can reduce infection rates significantly. Together, these two segments highlight a comprehensive approach to infection management in hospitals.

    Get more detailed insights about US Hospital Acquired infections Market

    Key Players and Competitive Insights

    The hospital acquired-infections market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on digital transformation. Key players such as Johnson & Johnson (US), Becton Dickinson and Company (US), and 3M Company (US) are actively pursuing strategies that enhance their market positioning. Johnson & Johnson (US) emphasizes innovation in infection prevention technologies, while Becton Dickinson and Company (US) focuses on expanding its product portfolio through strategic acquisitions. Meanwhile, 3M Company (US) is leveraging its expertise in materials science to develop advanced antimicrobial solutions, collectively contributing to a dynamic competitive environment.

    In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce operational costs. The market structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and solutions, fostering competition that drives innovation and improves patient outcomes.

    In October 2025, Johnson & Johnson (US) announced the launch of a new line of antimicrobial dressings designed to reduce the risk of surgical site infections. This strategic move not only reinforces the company's commitment to infection prevention but also positions it to capture a larger share of the growing market for advanced wound care products. The introduction of these dressings is expected to enhance patient safety and align with current healthcare trends emphasizing infection control.

    In September 2025, Becton Dickinson and Company (US) completed the acquisition of a leading diagnostics firm specializing in rapid testing for hospital-acquired infections. This acquisition is strategically significant as it expands Becton Dickinson's capabilities in the diagnostics space, allowing for quicker identification of pathogens and more effective infection management. The integration of rapid testing solutions into their existing product lines is likely to enhance their competitive edge in the market.

    In August 2025, 3M Company (US) launched a new digital platform aimed at streamlining infection prevention protocols in healthcare settings. This platform utilizes AI to analyze infection data and provide actionable insights to healthcare providers. The strategic importance of this initiative lies in its potential to improve compliance with infection control measures, thereby reducing the incidence of hospital-acquired infections and enhancing overall patient care.

    As of November 2025, current trends in the hospital acquired-infections market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering collaboration that enhances innovation and accelerates product development. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This shift underscores the importance of not only meeting regulatory standards but also exceeding them through proactive measures that prioritize patient safety and care.

    Key Companies in the US Hospital Acquired infections Market market include

    Industry Developments

    In recent months, the US Hospital-Acquired Infections Market has seen significant developments, particularly in the growth and valuation of key companies. Major players like Merck and Co. have reported increased investments in Research and Development initiatives aimed at innovative therapies and technologies to combat infections occurring in hospital settings. In June 2023, Becton Dickinson announced the expansion of its portfolio with advanced infection control products, enhancing its competitive stance within the market. Meanwhile, in September 2023, Abbott Laboratories launched a new diagnostic tool aimed at early detection of infections, reaffirming its commitment to addressing this critical issue.

    Mergers and acquisitions have also made headlines; in August 2023, 3M acquired a small biotech firm specializing in microbial prevention solutions, demonstrating strategic growth efforts in the sector. Siemens Healthineers has continued to bolster its presence with partnerships aimed at integrating advanced imaging technologies to mitigate hospital-acquired infections. Over the past few years, the market has experienced a rising demand for infection control solutions, with the increasing awareness of safety protocols amidst the ongoing concerns related to infectious diseases in healthcare establishments. These trends highlight the dynamic nature of the US Hospital-Acquired Infections Market.

    Future Outlook

    US Hospital Acquired infections Market Future Outlook

    The hospital acquired-infections market is projected to grow at 1.94% CAGR from 2024 to 2035, driven by advancements in infection control technologies and increased regulatory focus.

    New opportunities lie in:

    • Development of advanced antimicrobial coatings for medical devices
    • Implementation of AI-driven infection surveillance systems
    • Expansion of telehealth services for post-discharge monitoring

    By 2035, the market is expected to demonstrate robust growth, reflecting enhanced infection management strategies.

    Market Segmentation

    US Hospital Acquired infections Market Pathogen Type Outlook

    • Bacteria
    • Viruses
    • Fungi
    • Parasites

    US Hospital Acquired infections Market Infection Type Outlook

    • Surgical Site Infections
    • Ventilator-Associated Pneumonia
    • Catheter-Associated Urinary Tract Infections
    • Bloodstream Infections

    US Hospital Acquired infections Market Treatment Type Outlook

    • Infection Control Products
    • Antibiotics
    • Disinfectants
    • Vaccines

    US Hospital Acquired infections Market Hospital Department Outlook

    • Intensive Care Unit
    • Surgery Department
    • Emergency Department
    • Pediatric Department

    Report Scope

    MARKET SIZE 2024 8.5(USD Billion)
    MARKET SIZE 2025 8.66(USD Billion)
    MARKET SIZE 2035 10.5(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 1.94% (2024 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2019 - 2024
    Market Forecast Units USD Billion
    Key Companies Profiled Johnson & Johnson (US), Becton Dickinson and Company (US), 3M Company (US), Medtronic plc (IE), Stryker Corporation (US), Abbott Laboratories (US), Cardinal Health, Inc. (US), Thermo Fisher Scientific Inc. (US)
    Segments Covered Pathogen Type, Infection Type, Hospital Department, Treatment Type
    Key Market Opportunities Integration of advanced diagnostic technologies enhances infection control in the hospital acquired-infections market.
    Key Market Dynamics Rising regulatory scrutiny and technological advancements drive innovation in hospital acquired-infections prevention and management.
    Countries Covered US

    Leave a Comment

    FAQs

    What is the expected market size of the US Hospital-Acquired Infections Market in 2024?

    The US Hospital-Acquired Infections Market is expected to be valued at 10.5 USD Billion in 2024.

    What is the projected market size by 2035 for the US Hospital-Acquired Infections Market?

    By 2035, the US Hospital-Acquired Infections Market is anticipated to reach a valuation of 16.0 USD Billion.

    What is the expected CAGR for the US Hospital-Acquired Infections Market from 2025 to 2035?

    The expected CAGR for the US Hospital-Acquired Infections Market from 2025 to 2035 is 3.903%.

    Which pathogen type holds the largest market share in the US Hospital-Acquired Infections Market?

    Bacteria is expected to hold the largest market share, valued at 4.5 USD Billion in 2024, projected to grow to 7.0 USD Billion in 2035.

    What are some key players in the US Hospital-Acquired Infections Market?

    Major players include Parker Hannifin, Laboratory Corporation of America, Merck and Co., Medtronic, and Abbott Laboratories.

    What is the market size for viruses in the US Hospital-Acquired Infections Market by 2035?

    The market size for viruses is projected to reach 4.0 USD Billion by 2035.

    How much is the fungi segment of the US Hospital-Acquired Infections Market valued at in 2024?

    The fungi segment of the US Hospital-Acquired Infections Market is valued at 2.0 USD Billion in 2024.

    What growth opportunities exist in the US Hospital-Acquired Infections Market?

    Opportunities include advancements in infection prevention technologies and increasing awareness regarding hospital-acquired infections.

    What challenges are faced by the US Hospital-Acquired Infections Market?

    Challenges include stringent regulations and the growing prevalence of antibiotic-resistant pathogens.

    How is the parasites segment expected to perform by 2035 in the US Hospital-Acquired Infections Market?

    The parasites segment is expected to grow from 1.5 USD Billion in 2024 to 2.0 USD Billion by 2035.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions